{"meta":{"query_hash":"2cebe55bf556","filters":{"venue":"EAU-EBU Update Series"},"cohort_total":1,"direct_labels_cover":0,"predictions_cover":1,"exported":1,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/2cebe55bf556","api":"https://metacan.xera.ac/api/v1/cohort?venue=EAU-EBU+Update+Series"},"results":[{"id":"W2038344188","doi":"10.1016/j.eeus.2006.05.001","title":"Novel Therapies in Advanced Prostate Cancer","year":2006,"lang":"en","type":"article","venue":"EAU-EBU Update Series","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Docetaxel; Prostate cancer; Medicine; Oncology; Internal medicine; Cancer; Angiogenesis; Prostate; Bevacizumab; Refractory (planetary science); Clinical trial; Pharmacology; Chemotherapy; Biology","score_opus":0.013012467642178841,"score_gpt":0.2983800072524225,"score_spread":0.28536753961024364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038344188","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008540875,0.96874666,0.00077209907,0.0051379697,0.002381861,0.000061523795,0.00032105835,0.000053511914,0.013984395],"genre_scores_gemma":[0.07408758,0.8978896,0.0034104197,0.0035018462,0.00455709,0.00018564504,0.0009035343,0.000026133908,0.015438305],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99978715,0.000069179885,0.000022382934,0.000021471207,0.000063015614,0.000036745118],"domain_scores_gemma":[0.999668,0.00015603343,0.000051487696,0.000020941708,0.000057422407,0.000046124936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009031193,0.00033979013,0.0010184544,0.0011592491,0.0002789983,0.00082293357,0.0004861896,0.0006851197,0.008943135],"category_scores_gemma":[0.00072757946,0.0001394506,0.0006230013,0.0008766748,0.00025707728,0.00093047123,0.00041125703,0.0010305975,0.0014695801],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069766346,0.00038497162,0.0011201332,0.002033119,0.00010645896,0.00037089322,0.000052086427,0.00039896287,0.0026920855,0.0019683007,0.038467847,0.9517074],"study_design_scores_gemma":[0.0011098589,0.0037893243,0.010054004,0.0014340824,0.0005629194,0.0035810885,0.00013637781,0.0006964408,0.003980209,0.0030618054,0.97156376,0.00002993304],"about_ca_topic_score_codex":0.00044726723,"about_ca_topic_score_gemma":0.0024374572,"teacher_disagreement_score":0.008943135,"about_ca_system_score_codex":0.00046469914,"about_ca_system_score_gemma":0.00057579455,"threshold_uncertainty_score":0.029917777},"labels":[],"label_agreement":null}]}